

Maartje J Hooning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/843650/publications.pdf>

Version: 2024-02-01

114
papers

15,026
citations

41339

49
h-index

20955

115
g-index

117
all docs

117
docs citations

117
times ranked

18693
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. <i>Breast</i> , 2022, 61, 98-107.	2.2	6
2	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	5.0	15
3	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	1
4	Common Susceptibility Loci for Male Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 453-461.	6.3	12
5	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 205-214.	2.5	19
6	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMONY Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	1.0	9
7	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
8	Breast Cancer Risk Genes “ Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	27.0	532
9	Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. <i>Cancers</i> , 2021, 13, 2506.	3.7	17
10	The predictive ability of the 313 variant“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
11	Identification of Risk of Cardiovascular Disease by Automatic Quantification of Coronary Artery Calcifications on Radiotherapy Planning CT Scans in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1024.	7.1	35
12	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86.	5.0	7
13	The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. <i>Menopause</i> , 2021, Publish Ahead of Print, 1307-1312.	2.0	2
14	Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing. <i>Breast</i> , 2021, 58, 80-87.	2.2	5
15	Heart failure after treatment for breast cancer. <i>European Journal of Heart Failure</i> , 2020, 22, 366-374.	7.1	28
16	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
17	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
18	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. <i>JAMA Oncology</i> , 2020, 6, 1381.	7.1	31

#	ARTICLE	IF	CITATIONS
19	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
20	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5
21	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. Npj Breast Cancer, 2020, 6, 60.	5.2	9
22	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
23	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
24	The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer. Breast, 2020, 52, 102-109.	2.2	2
25	Prognosis of acute coronary syndromes after radiotherapy for breast cancer. Radiotherapy and Oncology, 2020, 146, 110-117.	0.6	6
26	The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysis. Cancer Causes and Control, 2020, 31, 403-416.	1.8	20
27	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
28	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
29	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	5.0	41
30	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
31	The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2020, 181, 581-588.	2.5	10
32	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 177, 723-733.	2.5	111
33	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
34	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1136-1147.	10.7	112
35	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
36	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24

#	ARTICLE	IF	CITATIONS
37	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2019, 44, 1-14.	2.2	42
38	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	6.2	711
39	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 1130-1139.	1.4	29
40	Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 595-604.	0.8	80
41	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. <i>International Journal of Cancer</i> , 2018, 143, 746-757.	5.1	19
42	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, 6574.	3.3	51
43	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 408-418.	6.4	50
44	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017, 49, 834-841.	21.4	426
45	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	7.4	1,898
46	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
47	Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 85, 31-38.	2.8	32
48	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	27.8	1,099
49	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
50	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	1.9	45
51	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	1.8	14
52	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. <i>Oncotarget</i> , 2017, 8, 102769-102782.	1.8	9
53	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	1.8	31
54	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	8.4	118

#	ARTICLE	IF	CITATIONS
55	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 2016, 139, 1303-1317.	5.1	51
56	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
57	Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk. Scientific Reports, 2016, 6, 30026.	3.3	3
58	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
59	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
60	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	2.9	33
61	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	3.3	2
62	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
63	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
64	Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	5.0	56
65	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CH</i> <i>EK</i> <i>2</i> *1100delC Carriers. Journal of Clinical Oncology, 2016, 34, 2750-2760.	1.6	152
66	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2016, 2, 138-153.	3.0	19
67	Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. British Journal of Cancer, 2016, 114, 631-637.	6.4	99
68	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
69	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
70	Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. Journal of Clinical Oncology, 2016, 34, 409-418.	1.6	84
71	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
72	Improved overall survival after contralateral risk-reducing mastectomy in <i>BRCA1/2</i> mutation carriers with a history of unilateral breast cancer: A prospective analysis. International Journal of Cancer, 2015, 136, 668-677.	5.1	158

#	ARTICLE	IF	CITATIONS
73	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer, 2015, 15, 978.	2.6	6
74	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
75	Survival benefit in women with <i>BRCA1</i> mutation or familial risk in the <scp>MRI</scp> screening study (<scp>MRISC</scp>). International Journal of Cancer, 2015, 137, 1729-1738.	5.1	78
76	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	1.8	20
77	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
78	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine, 2015, 2, 681-689.	6.1	56
79	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature. Cancer Treatment Reviews, 2015, 41, 187-196.	7.7	47
80	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
81	Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer. Human Pathology, 2015, 46, 182-190.	2.0	23
82	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
83	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37
84	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
85	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 2015, 47, 1294-1303.	21.4	357
86	Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. Breast Cancer Research and Treatment, 2015, 154, 171-180.	2.5	32
87	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Medicine, 2015, 13, 156.	5.5	51
88	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
89	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
90	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	1.8	15

#	ARTICLE	IF	CITATIONS
91	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
92	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
93	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
94	Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. Cancer Biology and Therapy, 2014, 15, 371-379.	3.4	6
95	Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Research and Treatment, 2014, 144, 577-582.	2.5	66
96	Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. International Journal of Cancer, 2014, 135, 2940-2949.	5.1	13
97	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	27.8	548
98	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
99	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
100	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
101	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
102	Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	1.6	148
103	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
104	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
105	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
106	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
107	Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	2.5	79
108	CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. Journal of Clinical Oncology, 2012, 30, 4308-4316.	1.6	162

#	ARTICLE	IF	CITATIONS
109	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	2.9	80
110	The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer, 2012, 118, 899-907.	4.1	83
111	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
112	<i>BRCA1</i> -Associated Breast Cancers Present Differently From <i>BRCA2</i> -Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology, 2010, 28, 5265-5273.	1.6	166
113	Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5561-5568.	1.6	96
114	Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 365-375.	6.3	715